[Influence of therapy with atenolol on lethality of patients with chronic heart failure].
The paper demonstrates that the hydrophilic beta-adrenoblocker (BAB) atenolol is effective in patients with III-IV functional class chronic heart failure (CHF), associated with postinfarction cardiosclerosis (PIC) and dilatational cardiomyopathy (DC). In reduction of general and cardiovascular mortality in the given category of patients atenolol was not less effective than the lipophilic BAB bisoprolol (in comparison with the results of the CIBIS II study). Sudden death was typical of the patients with DC, whereas most of PC patients died of repeated myocardial infarctions and progressive CHF. There was no significant difference between lethality in DC and PIC groups (p > 0.05). The results of the study suggest that hydrophilic BABs are not less effective in improving the prognosis than lipophilic BABs. Further research into this problem is appropriate.